Michael P Poirier MD
Associate Professor, Pediatrics, Eastern Virginia Medical School
Join to View Full Profile
601 Childrens LnNorfolk, VA 23507
Phone+1 757-668-9222
Fax+1 757-668-7568
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Poirier, MD is a pediatric emergency medicine physician in Norfolk, Virginia. He is currently licensed to practice medicine in Virginia, Ohio, and Georgia. He is an Associate Professor at Eastern Virginia Medical School.
Education & Training
University of Alabama Medical CenterResidency, Pediatrics, 1990 - 1993
University of Alabama School of MedicineClass of 1990
Certifications & Licensure
VA State Medical License 1996 - 2026
OH State Medical License 1994 - 1996
GA State Medical License 1993 - 1995
AL State Medical License 1991 - 1993
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Emergency Medicine
Publications & Presentations
PubMed
- 9 citationsPropofol Versus Dexmedetomidine for Procedural Sedation in a Pediatric Population.Nicole M Schacherer, Tamara M. Armstrong, Amy M. Perkins, Michael P Poirier, James M Schmidt
Southern Medical Journal. 2019-05-01 - 2 citationsEmergency Department Diagnosis of Dietl Crisis in a 7-Year-Old Girl With Abdominal Pain.James Burhop, Joel Clingenpeel, Michael P. Poirier
Pediatric Emergency Care. 2016-06-01 - 4 citationsInternal Applicants to Pediatric Emergency Medicine Fellowships and Current Use of the National Resident Matching Program Match: A Survey of Fellowship Directors.Timothy Bradley, Joel Clingenpeel, Michael P. Poirier
Pediatric Emergency Care. 2015-07-01
Press Mentions
- Qualigen Calls It Quits on COVID Antiviral After Pouring Millions into R&DAugust 17th, 2021
- Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial ResultsAugust 17th, 2021
- Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19July 14th, 2021
- Join now to see all
